Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

OncoAlert and ecancer weekly roundup for September 6-13, 2020

Published: 14 Sep 2020

Views: 1313

Rating:

Save

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of September 6 - 13.

Dr Morgan covers papers from The Lancet Oncology, Nature, The Journal of Global Oncology, The New England Journal of Medicine, The Journal of Clinical Oncology, JAMA Oncology, The European Journal of Cancer, Cancer Discovery, WHO, and Cancer Discovery.

He also reminds us about the Oncoalert podcast and newsletter.

You can watch Dr Morgan's previous roundup for August 30 - September 6 2020 here.

Follow Dr Morgan on twitter.

Follow ecancer on twitter.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible...

Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York...

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial...

Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )

More from ecancer